Early Detection of Psychosis: Recent Updates from Clinical High-Risk Research

Current Behavioral Neuroscience Reports

Volumn 2, Issue 2, 2015, Pages 90-101

  Schvarcz, Ariel ^a   Bearden, Carrie E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical functioning; Clinical high risk; Early detection; Neurocognition; Neuroimaging; Psychosis

Indexed keywords

EID: 84955454128     PISSN: None     EISSN: 21962979     Source Type: Journal    
DOI: 10.1007/s40473-015-0033-6     Document Type: Review

References (92)

1. Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. JAMA. 2013;310(7):689–90. doi:10.1001/jama.2013.8804. DOI: 10.1001/jama.2013.8804
2. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88–94. doi:10.1192/bjp.bp.113.127753. DOI: 10.1192/bjp.bp.113.127753
3. Birchwood M, Connor C, Lester H, Patterson P, Freemantle N, Marshall M, et al. Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatr. 2013;203(1):58–64. doi:10.1192/bjp.bp.112.125500. DOI: 10.1192/bjp.bp.112.125500
4. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15. DOI: 10.1093/oxfordjournals.schbul.a007040
5. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatr. 2005;39(11–12):964–71. doi:10.1111/j.1440-1614.2005.01714.x. DOI: 10.1080/j.1440-1614.2005.01714.x
6. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatr. 2013;70(1):107–20. doi:10.1001/jamapsychiatry.2013.269. Thorough synthesis of CHR literature suggests vulnerability markers exist in all reviewed domains but with little certainty on their diagnostic specificity. DOI: 10.1001/jamapsychiatry.2013.269
7. O’Connor K. Research in young people at ultra-high risk for psychosis: a review of the current evidence. Ir J Psychol Med. 2013;30(01):77–89. doi:10.1017/ipm.2012.9. DOI: 10.1017/ipm.2012.9
8. Gur RE. Early detection of psychosis: challenges and opportunities. Curr Behav Neurosci Rep. 2014;1(2):117–24. doi:10.1007/s40473-014-0012-3. Recent review of clinical-high risk literature with focus on methods of neural assessment (e.g., neurotransmitters, neuroimaging, etc.). DOI: 10.1007/s40473-014-0012-3
9. Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, et al. Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res. 2014;158(1–3):69–75. doi:10.1016/j.schres.2014.06.022. DOI: 10.1016/j.schres.2014.06.022
10. DeVylder JE, Ben-David S, Schobel SA, Kimhy D, Malaspina D, Corcoran CM. Temporal association of stress sensitivity and symptoms in individuals at clinical high risk for psychosis. Psychol Med. 2013;43(02):259–68. doi:10.1017/S0033291712001262. DOI: 10.1017/S0033291712001262
11. Meyer EC, Carrión RE, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD et al. The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. Schizophr Bull. 2014;sbt235. doi:10.1093/schbul/sbt235.
12. Kohler CG, Richard JA, Brensinger CM, Borgmann-Winter KE, Conroy CG, Moberg PJ, et al. Facial emotion perception differs in young persons at genetic and clinical high-risk for psychosis. Psychiatr Res. 2014;216(2):206–12. doi:10.1016/j.psychres.2014.01.023. DOI: 10.1016/j.psychres.2014.01.023
13. Yong E, Barbato M, Penn DL, Keefe RSE, Woods SW, Perkins DO, et al. Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Res. 2014;218(1–2):39–43. doi:10.1016/j.psychres.2014.04.003. DOI: 10.1016/j.psychres.2014.04.003
14. Tarbox SI, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO et al. Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol. 2013;25(4pt1):1171–1186. doi:10.1017/S0954579413000448. DOI: 10.1017/S0954579413000448
15. Tarbox SI, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, et al. Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. Psychiatr Res. 2014;215(1):52–60. doi:10.1016/j.psychres.2013.10.006. DOI: 10.1016/j.psychres.2013.10.006
16. Tsuji T, Kline E, Sorensen HJ, Mortensen EL, Michelsen NM, Ekstrom M, et al. Premorbid teacher-rated social functioning predicts adult schizophrenia-spectrum disorder: a high-risk prospective investigation. Schizophr Res. 2013;151(1–3):270–3. doi:10.1016/j.schres.2013.10.022. DOI: 10.1016/j.schres.2013.10.022
17. Carrión RE, McLaughlin D, Goldberg TE, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatr. 2013;70(11):1133–42. doi:10.1001/jamapsychiatry.2013.1909. DOI: 10.1001/jamapsychiatry.2013.1909
18. Walder DJ, Holtzman CW, Addington J, Cadenhead K, Tsuang M, Cornblatt B, et al. Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophr Res. 2013;144:43–50. doi:10.1016/j.schres.2012.11.039. DOI: 10.1016/j.schres.2012.11.039
19. Velthorst E, Derks EM, Schothorst P, Becker H, Durston S, Ziermans T, et al. Quantitative and qualitative symptomatic differences in individuals at ultra-high risk for psychosis and healthy controls. Psychiatr Res. 2013;210(2):432–7. doi:10.1016/j.psychres.2013.07.018. DOI: 10.1016/j.psychres.2013.07.018
20. Ziermans T, de Wit S, Schothorst P, Sprong M, van Engeland H, Kahn R, et al. Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS ONE. 2014;9(4):e93994. doi:10.1371/journal.pone.0093994. DOI: 10.1371/journal.pone.0093994
21. Velthorst E, Nelson B, Wiltink S, de Haan L, Wood SJ, Lin A, et al. Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? Schizophr Res. 2013;143(1):132–7. doi:10.1016/j.schres.2012.10.025. DOI: 10.1016/j.schres.2012.10.025
22. Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophr Res. 2014;156(2–3):277–80. doi:10.1016/j.schres.2014.04.021. DOI: 10.1016/j.schres.2014.04.021
23. Addington J, Case N, Saleem MM, Auther AM, Cornblatt BA, Cadenhead KS. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatr. 2014;8(2):104–12. doi:10.1111/eip.12100. DOI: 10.1111/eip.12100
24. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007;151(1–2):151–4. doi:10.1016/j.psychres.2006.10.001. DOI: 10.1016/j.psychres.2006.10.001
25. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28–37. doi:10.1001/archgenpsychiatry.2007.3. DOI: 10.1001/archgenpsychiatry.2007.3
26. Rapp C, Walter A, Studerus E, Bugra H, Tamagni C, Röthlisberger M et al. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatr Res: Neuroimaging. 2013;214(2):102–108. doi:10.1016/j.pscychresns.2013.06.006. DOI: 10.1016/j.pscychresns.2013.06.006
27. Thompson AD, Nelson B, Yuen HP, Lin A, Amminger GP, McGorry PD et al. Sexual trauma increases the risk of developing psychosis in an ultra high-risk “prodromal” population. Schizophr Bull. 2013;sbt032. doi:10.1093/schbul/sbt032.
28. Magaud E, Morvan Y, Rampazzo A, Alexandre C, Willard D, Gaillard R et al. Subjects at ultra high risk for psychosis have “heterogeneous” intellectual functioning profile: a multiple-case study. Schizophr Res. 2014;152(2–3), 415–420. doi:10.1016/j.schres.2013.11.002. DOI: 10.1016/j.schres.2013.11.002
29. Michel C, Ruhrmann S, Schimmelmann BG, Klosterkötter J, Schultze-Lutter F. A stratified model for psychosis prediction in clinical practice. Schizophr Bull. 2014;sbu025. doi:10.1093/schbul/sbu025.
30. Bora E, Lin A, Wood SJ, Yung AR, McGorry PD, Pantelis C. Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. Acta Psychiatr Scand. 2014;130(1):1–15. doi:10.1111/acps.12261. Review of neurocognitive studies reveals presence of widespread premorbid deficits that confer vulnerability for later psychosis onset. DOI: 10.1111/acps.12261
31. Woodberry KA, McFarlane WR, Giuliano AJ, Verdi MB, Cook WL, Faraone SV, et al. Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophr Res. 2013;146(1–3):87–94. doi:10.1016/j.schres.2013.01.017. DOI: 10.1016/j.schres.2013.01.017
32. Lee TY, Shin YS, Shin NY, Kim SN, Jang JH, Kang D-H, et al. Neurocognitive function as a possible marker for remission from clinical high risk for psychosis. Schizophr Res. 2014;153(1–3):48–53. doi:10.1016/j.schres.2014.01.018. DOI: 10.1016/j.schres.2014.01.018
33. Hohenberg CC, von, Pasternak O, Kubicki M, Ballinger T, Vu M-A, Swisher T et al. White matter microstructure in individuals at clinical high risk of psychosis: a whole-brain diffusion tensor imaging study. Schizophr. Bull. 2013;sbt079. doi:10.1093/schbul/sbt079.
34. Bois C, Whalley HC, McIntosh AM, Lawrie SM. Structural magnetic resonance imaging markers of susceptibility and transition to schizophrenia: a review of familial and clinical high risk population studies. J Psychopharmacol. 2014. doi:10.1177/0269881114541015. Review of neuroimaging studies suggests structural abnormalities precede psychosis onset and provide a useful prediction framework.
35. Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MAP, Bhattacharyya S, Allen P et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatr. 2013;74(2):106–112. doi:10.1016/j.biopsych.2012.11.017. DOI: 10.1016/j.biopsych.2012.11.017
36. Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Ilankovic L et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull. 2014;sbu078. doi:10.1093/schbul/sbu078.
37. Fusar-Poli P, Borgwardt S, Crescini A, Deste G, Kempton MJ, Lawrie S et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev. 2011;35(5), 1175–1185. doi:10.1016/j.neubiorev.2010.12.005. DOI: 10.1016/j.neubiorev.2010.12.005
38. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J et al. Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis. Neurosci Biobehav Rev. 2010;34(8):1207–1222. doi:10.1016/j.neubiorev.2010.01.016. DOI: 10.1016/j.neubiorev.2010.01.016
39. Takahashi T, Wood SJ, Yung AR, Phillips LJ, Soulsby B, McGorry PD et al. Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophr Res. 2009;111(1–3):94–102. doi:10.1016/j.schres.2009.03.024. DOI: 10.1016/j.schres.2009.03.024
40. Takahashi T, Wood SJ, Yung AR, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry. 2009;66(4):366–76. doi:10.1001/archgenpsychiatry.2009.12. DOI: 10.1001/archgenpsychiatry.2009.12
41. Tognin S, Riecher-Rössler A, Meisenzahl EM, Wood SJ, Hutton C, Borgwardt SJ et al. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. Psychol Med. 2014;44(03):489–498. doi:10.1017/S0033291713000998. DOI: 10.1017/S0033291713000998
42. Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TGM et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatr. 2015;77:147–57. doi:10.1016/j.biopsych.2014.05.023. DOI: 10.1016/j.biopsych.2014.05.023
43. Van Tricht MJ, Ruhrmann S, Arns M, Müller R, Bodatsch M, Velthorst E et al. Can quantitative EEG measures predict clinical outcome in subjects at clinical high risk for psychosis? A prospective multicenter study. Schizophr Res. 2014;153(1):42–47. doi:10.1016/j.schres.2014.01.019. DOI: 10.1016/j.schres.2014.01.019
44. Andreou C, Faber PL, Leicht G, Schoettle D, Polomac N, Hanganu-Opatz IL et al. Resting-state connectivity in the prodromal phase of schizophrenia: insights from EEG microstates. Schizophr Res. 2014;152(2–3):513–520. doi:10.1016/j.schres.2013.12.008. DOI: 10.1016/j.schres.2013.12.008
45. Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, et al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry. 2014;75(6):459–69. doi:10.1016/j.biopsych.2013.07.038. DOI: 10.1016/j.biopsych.2013.07.038
46. Walker EF, Trotman HD, Goulding SM, Holtzman CW, Ryan AT, McDonald A et al. Developmental mechanisms in the prodrome to psychosis. Dev Psychopathol. 2013;25(25th Anniversary Special Issue 4pt2):1585–1600. doi:10.1017/S0954579413000783.
47. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008;4(1):189–216. doi:10.1146/annurev.clinpsy.4.022007.141248. DOI: 10.1146/annurev.clinpsy.4.022007.141248
48. Day FL, Valmaggia LR, Mondelli V, Papadopoulos A, Papadopoulos I, Pariante CM, et al. Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophr Res. 2014;158(1–3):25–31. doi:10.1016/j.schres.2014.06.041. DOI: 10.1016/j.schres.2014.06.041
49. Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA et al. Cortisol levels and risk for psychosis: initial findings from the North American Prodrome Longitudinal Study. Biol. Psychiatr. 2013;74(6):410–417. doi:10.1016/j.biopsych.2013.02.016. DOI: 10.1016/j.biopsych.2013.02.016
50. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry. 2014;75(4):324–31. doi:10.1016/j.biopsych.2013.09.037. DOI: 10.1016/j.biopsych.2013.09.037
51. Hui C, Morcillo C, Russo DA, Stochl J, Shelley GF, Painter M et al. Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for psychosis. Schizophr Res. 2013;148(1–3):175–180. doi:10.1016/j.schres.2013.05.026. DOI: 10.1016/j.schres.2013.05.026
52. Manninen M, Lindgren M, Therman S, Huttunen M, Ebeling H, Moilanen I, et al. Clinical high-risk state does not predict later psychosis in a delinquent adolescent population. Early Interv Psychiatr. 2014;8(1):87–90. doi:10.1111/eip.12045. DOI: 10.1111/eip.12045
53. Lindgren M, Manninen M, Kalska H, Mustonen U, Laajasalo T, Moilanen K et al. Predicting psychosis in a general adolescent psychiatric sample. Schizophr Res. 2014;158(1–3):1–6. doi:10.1016/j.schres.2014.06.028. DOI: 10.1016/j.schres.2014.06.028
54. Fisher HL, Caspi A, Poulton R, Meier MH, Houts R, Harrington H et al. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol Med. 2013;43(10):2077–2086. doi:10.1017/S0033291712003091. DOI: 10.1017/S0033291712003091
55. De Wit S, Schothorst PF, Oranje B, Ziermans TB, Durston S, Kahn RS. Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state. Eur Neuropsychopharmacol. 2014;24(6):865–73. doi:10.1016/j.euroneuro.2014.02.008. DOI: 10.1016/j.euroneuro.2014.02.008
56. Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatr Scand. 2013;127(3):248–52. doi:10.1111/acps.12028. DOI: 10.1111/acps.12028
57. Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2014;44(01):17–24. doi:10.1017/S0033291713000184. DOI: 10.1017/S0033291713000184
58. Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P. Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res. 2013;209(3):266–72. doi:10.1016/j.psychres.2013.03.004. DOI: 10.1016/j.psychres.2013.03.004
59. Schultze-Lutter F, Klosterkötter J, Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res. 2014;154(1–3):100–6. doi:10.1016/j.schres.2014.02.010. DOI: 10.1016/j.schres.2014.02.010
60. Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, et al. At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull. 2013;39(4):923–32. doi:10.1093/schbul/sbs060. DOI: 10.1093/schbul/sbs060
61. Gale C, Glue P, Gallagher S. Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA Psychiatr. 2013;70(8):880–1. doi:10.1001/jamapsychiatry.2013.1320. DOI: 10.1001/jamapsychiatry.2013.1320
62. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 (5 edition.). Washington, D.C.: American Psychiatric Publishing; 2013.
63. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated psychosis syndrome: ready for DSM-5.1? Annu Rev Clin Psychol. 2014;10(1):155–92. doi:10.1146/annurev-clinpsy-032813-153645. DOI: 10.1146/annurev-clinpsy-032813-153645
64. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013;150(1):31–35. doi:10.1016/j.schres.2013.05.004. DOI: 10.1016/j.schres.2013.05.004
65. Shah JL, Tandon N, Keshavan MS. Psychosis prediction and clinical utility in familial high-risk studies: selective review, synthesis, and implications for early detection and intervention. Early Interv Psychiatr. 2013;7(4):345–60. doi:10.1111/eip.12054. Literature review of predictors of psychosis among genetic high-risk cohorts suggests no existing markers for accurate prediction. DOI: 10.1111/eip.12054
66. Singh F, DeJoseph M, Cadenhead KS. Therapeutic considerations in individuals at clinical risk for developing psychosis. Curr Treat Options Psychiatr. 2014;1(2):134–48. doi:10.1007/s40501-014-0009-2. DOI: 10.1007/s40501-014-0009-2
67. Liu C-C, Demjaha A. Antipsychotic interventions in prodromal psychosis. CNS Drugs. 2013;27(3):197–205. doi:10.1007/s40263-013-0046-1. DOI: 10.1007/s40263-013-0046-1
68. Mossaheb N, Schäfer MR, Schlögelhofer M, Klier CM, Cotton SM, McGorry PD, et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? Schizophr Res. 2013;148(1–3):163–7. doi:10.1016/j.schres.2013.05.027. DOI: 10.1016/j.schres.2013.05.027
69. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D’Souza DC et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013;23(8):931–940. doi:10.1016/j.euroneuro.2012.09.008. DOI: 10.1016/j.euroneuro.2012.09.008
70. Van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149(1–3):56–62. doi:10.1016/j.schres.2013.07.004. DOI: 10.1016/j.schres.2013.07.004
71. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med. 2014;44(03):449–68. doi:10.1017/S0033291713000354. DOI: 10.1017/S0033291713000354
72. Okuzawa N, Kline E, Fuertes J, Negi S, Reeves G, Himelhoch S, Schiffman J. Psychotherapy for adolescents and young adults at high risk for psychosis: a systematic review. Early Interv Psychiatr. 2014;n/a–n/a. doi:10.1111/eip.12129.
73. Byrne RE, Morrison AP. Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychol Psychother Theory Res Pract. 2014;87(3):357–71. doi:10.1111/papt.12013. DOI: 10.1111/papt.12013
74. Miklowitz DJ, O’Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatr. 2014;53(8):848–858. doi:10.1016/j.jaac.2014.04.020. DOI: 10.1016/j.jaac.2014.04.020
75. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013;9(1):435–63. doi:10.1146/annurev-clinpsy-032511-143134. DOI: 10.1146/annurev-clinpsy-032511-143134
76. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346(jan18 1), f185–f185. doi:10.1136/bmj.f185. Reviews randomized trials of psychological, pharmacological, and nutritional treatments as possible psychosis prevention methods and suggests some evidence for cognitive behavioral therapy and omega-3 fatty acids.
77. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatr. 2013;74(04):349–356. doi:10.4088/JCP.12m07785. DOI: 10.4088/JCP.12m07785
78. Fridgen GJ, Aston J, Gschwandtner U, Pflueger M, Zimmermann R, Studerus E et al. Help-seeking and pathways to care in the early stages of psychosis. Social Psychiatr Psychiatr Epidemiol. 2013;48(7):1033–1043. doi:10.1007/s00127-012-0628-0. DOI: 10.1007/s00127-012-0628-0
79. Von Reventlow HG, Krüger-Özgürdal S, Ruhrmann S, Schultze-Lutter F, Heinz A, Patterson P et al. Pathways to care in subjects at high risk for psychotic disorders—a European perspective. Schizophr Res. 2014;152(2–3):400–407. doi:10.1016/j.schres.2013.11.031. DOI: 10.1016/j.schres.2013.11.031
80. Alderman T, Addington J, Bearden C, Cannon TD, Cornblatt BA, McGlashan TH et al. Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Interv Psychiatr. 2014; doi:10.1111/eip.12128. DOI: 10.1111/eip.12128
81. Hughes F, Stavely H, Simpson R, Goldstone S, Pennell K, McGorry P. At the heart of an early psychosis centre: the core components of the 2014 Early Psychosis Prevention and Intervention Centre model for Australian communities. Aust Psychiatr. 2014;22(3):228–34. doi:10.1177/1039856214530479. DOI: 10.1177/1039856214530479
82. Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol. 2013;9(1):465–97. doi:10.1146/annurev-clinpsy-050212-185620. DOI: 10.1146/annurev-clinpsy-050212-185620
83. Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet. 2014;383(9926):1395–1403. doi:10.1016/S0140-6736(13)62246-1. DOI: 10.1016/S0140-6736(13)62246-1
84. Khoury B, Lecomte T, Gaudiano BA, Paquin K. Mindfulness interventions for psychosis: a meta-analysis. Schizophr Res. 2013;150(1):176–84. doi:10.1016/j.schres.2013.07.055. DOI: 10.1016/j.schres.2013.07.055
85. Morrison AP, Pyle M, Chapman N, French P, Parker SK, Wells A. Metacognitive therapy in people with a schizophrenia spectrum diagnosis and medication resistant symptoms: a feasibility study. J Behav Ther Exp Psychiatry. 2014;45(2):280–4. doi:10.1016/j.jbtep.2013.11.003. DOI: 10.1016/j.jbtep.2013.11.003
86. Hedman AM, van Haren NEM, van Baal CGM, Kahn RS, Hulshoff Pol HE. IQ change over time in schizophrenia and healthy individuals: a meta-analysis. Schizophr Res. 2013;146(1–3):201–8. doi:10.1016/j.schres.2013.01.027. DOI: 10.1016/j.schres.2013.01.027
87. Bowie CR, Grossman M, Gupta M, Oyewumi LK, Harvey PD. Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness. Early Interv Psychiatr. 2014;8(1):32–8. doi:10.1111/eip.12029. DOI: 10.1111/eip.12029
88. Puig O, Penadés R, Baeza I, De la Serna E, Sánchez-Gistau V, Bernardo M, et al. Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. J Am Acad Child Adolesc Psychiatr. 2014;53(8):859–68. doi:10.1016/j.jaac.2014.05.012. DOI: 10.1016/j.jaac.2014.05.012
89. Drake RJ, Day CJ, Picucci R, Warburton J, Larkin W, Husain N et al. A naturalistic, randomized, controlled trial combining cognitive remediation with cognitive–behavioural therapy after first-episode non-affective psychosis. Psychol Med. 2014;44(09):1889–1899. doi:10.1017/S0033291713002559. DOI: 10.1017/S0033291713002559
90. Tully LM, Niendam TA. Beyond “cold” cognition: exploring cognitive control of emotion as a risk factor for psychosis. Curr Behav Neurosci Rep. 2014;1(3):170–81. doi:10.1007/s40473-014-0016-z. DOI: 10.1007/s40473-014-0016-z
91. Kline E, Schiffman J. Psychosis risk screening: a systematic review. Schizophr Res. 2014;158(1–3):11–8. doi:10.1016/j.schres.2014.06.036. DOI: 10.1016/j.schres.2014.06.036
92. Zhang T, Li H, Woodberry KA, Seidman LJ, Zheng L, Li H et al. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res. 2014;152(2–3):391–399. doi:10.1016/j.schres.2013.11.039. DOI: 10.1016/j.schres.2013.11.039